Clinical Trial Update: A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AMNN107 in patients with metastatic melanoma harboring a c-KIT mutation has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• AMNN107

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2015-11-26